Pfiz­er wins a “break­through” ti­tle for ALK/ROS1 con­tender lor­la­tinib af­ter hus­tling in­to PhI­II

Last June at AS­CO, Pfiz­er re­searchers were hap­py to dis­cuss the pos­i­tive hu­man da­ta they had plumbed for lor­la­tinib (PF-06463922), their “next-gen­er­a­tion” ALK/ROS1 ty­ro­sine ki­nase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER